Multicenter Intravascular Ultrasound Validation Study Among Heart Transplant Recipients
Outcomes After Five Years
Jon A. Kobashigawa, MD, FACC*,*,
Jonathan M. Tobis, MD, FACC*,
Randall C. Starling, MD, MPH, FACC ,
E. Murat Tuzcu, MD, FACC ,
Andrew L. Smith, MD, FACC ,
Hannah A. Valantine, MD, FACC ,
Alan C. Yeung, MD, FACC ,
Mandeep R. Mehra, MD, FACC||,
Hitoshi Anzai, MD*,
Brandy T. Oeser, MPH*,
Kamal H. Abeywickrama, PhD¶,
Jane Murphy, BSN¶ and
Nathalie Cretin, MD¶
* University of California at Los Angeles, Los Angeles, California
Cleveland Clinic Foundation, Cleveland, Ohio
Emory University, Atlanta, Georgia
Stanford University, Stanford, California
|| Ochsner Clinic Foundation, New Orleans, Louisiana
¶ Novartis Pharma, Basel, Switzerland

View larger version (15K):
[in a new window]
|
Figure 1 Kaplan-Meier curve of death and/or graft loss by maximal intimal thickness (MIT) classification. Group 1 = MIT change 0.5 mm; group 2 = MIT change <0.5 mm. Vertical bars = ± SE.
|
|

View larger version (17K):
[in a new window]
|
Figure 2 Kaplan-Meier curve of nonfatal major adverse cardiac events and death and/or graft loss by maximal intimal thickness (MIT) classification. Group 1 = MIT change 0.5 mm; group 2 = MIT change <0.5 mm. Vertical bars = ± SE.
|
|
|